Overview
Povidone Iodine Nasal Application to Prevent Intraoperative Spread of SARS-CoV-2
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2025-04-01
2025-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The primary aim is to test whether preoperative asepsis with 5% nasal povidone iodine versus no preoperative asepsis with 5% nasal povidone iodine reduces proximal and distal SARS-CoV-2 transmission in operating rooms among patients who are acutely infected with SARS-CoV-2. The secondary aim is to test viral infectivity.Phase:
Phase 4Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Randy LoftusCollaborator:
3MTreatments:
Povidone
Povidone-Iodine
Criteria
Inclusion Criteria:- Adult patients
- Undergoing surgery (elective, urgent, or emergent)
- Requiring general anesthesia
- Acutely infected (<= 10 days from diagnosis) with SARS-CoV-2
Exclusion Criteria:
- Not general anesthesia
- Not acutely infected (<= 10 days from diagnosis) with SARS-CoV-2
- Allergy to povidone iodine
- Unable to provide consent
- Pregnant individuals